Integra LifeSciences Swings To Earnings In Q3; Guides Q4, FY26

Integra LifeSciences (IART) reported Q3 net income of $14.85M, up from a $5.40M loss last year. Revenue rose to $411.18M. The company guided Q4 revenue between $413M-$433M and FY26 revenue between $1.634B-$1.654B. Adjusted EPS for Q4 is expected to be $0.61-$0.71, and $2.30-$2.40 for FY26.

Original reporting
Published Oct 21, 2026, 10:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IART
Neutral
high confidence
Mentioned
$IART
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$IARTNeutralMed
01

Why it matters

The earnings beat may provide short‑term support, but the guidance indicating a revenue contraction could lead to a pullback. Traders should watch volume and any forward‑looking commentary from management.

02

Market read

Primary earnings release with fresh guidance; directly influences IART price and may affect peer med‑tech stocks.

03

What to watch

Potential upside from upcoming product launches or contract wins not disclosed in this release.

Relevance 8/10Novelty 8/10Timing: post-market

Background

Integra LifeSciences is a medical device and specialty surgical company listed on Nasdaq. The Q3 results mark a turnaround from a loss year‑over‑year.

Company-level read

Ticker impact

$IARTNeutralHigh confidence
Context

Integra LifeSciences reported Q3 profit and issued Q4 revenue guidance that shows a slight decline, providing fresh earnings data and guidance.

Expected impact

modest downside pressure as investors price in lower Q4 revenue guidance

Evidence & confidence

The earnings beat is offset by guidance that projects a revenue decline of up to 5.2%, which may trigger short‑term selling.

Market effects

Medical device sector may see slight pressure as guidance hints at slower growth, but overall sector remains stable.

U.S. market impact limited to healthcare stocks; no broader regional effect.

Minimal global relevance beyond investors tracking U.S. med‑tech equities.

Counterpoint

Despite the revenue dip, the profit swing and strong adjusted EBITDA could support a bounce if the market overreacts.

Key entities

  • Integra LifeSciences Holdings Corp.

    U.S.-listed medical device company reporting Q3 earnings and Q4 guidance.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.